The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
April 29th 2025
A novel orally bioavailable RIPTAC therapeutic targeting the p53-Y220C mutation demonstrates selective cancer cell killing by inducing proximity between mutant p53 and an essential protein, offering a promising new strategy for treating historically untreatable tumors.
Bisphosphonates' Growing Role in Breast Cancer
June 15th 2008Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patients—pharmacists need to recommend appropriate screening and treatment.
Read More